A New Weapon In Generic Drug Companies' Arsenal
Generic drug companies have seized on the U.S. Patent and Trademark Office's inter partes review proceeding as a new weapon in their assault on patents protecting branded drug products. Since the...To view the full article, register now.
Already a subscriber? Click here to view full article